1. In Vivo

Cipla CEO On Lung Leadership Beyond Asthma, AMR Plans

CEO Vohra Talks Strategy With Scrip

 
• By Anju Ghangurde

CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.  

Cipla CEO
Cipla CEO Umang Vohra

Cipla Limited’s lung leadership aspirations go well beyond its traditional stronghold of asthma and could encompass domains like oncology, alongside repurposing initiatives and breaking into new markets.

In an exclusive interview with In Vivo's sister publication Scrip, the Indian firm’s global CEO and managing director Umang Vohra outlined the many prongs of the company’s lung leadership aspirations,...

Biosimilars - 'The Door Is Never Closed'

Cipla had previously repositioned its resource-intensive biosimilars business, pivoting more towards a business development/in-licensing model. Is it open to...

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.